NEWSROOM

Discover the latest news
about Medison

01/08/24

PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]

30/04/24

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

01/02/24

PBS listing for Australians with unresectable or metastatic uveal melanoma

08/01/24

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

13/11/23

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

09/03/23

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

09/01/23

Sarah Otten Joins Medison Pharma as VP, GM Americas Region

09/11/22

Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America

22/08/22

Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients

16/08/22

Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

06/06/22

Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel

23/05/22

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

28/03/22

Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefirix[®] (imlifidase) for desensitization treatment of highly sensitized kidney transplant patients

15/03/22

BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

26/01/22

Victor Papamoniodis Joins Medison Pharma as VP International Markets

07/12/21

Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel

18/10/21

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

22/07/21

Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel

07/06/21

Moderna and Medison Pharma partner to commercialize Moderna’s COVID-19 vaccine across Central Eastern Europe and Israel

08/03/21

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

04/02/21

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

23/11/20

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

06/11/20

Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement

15/06/20

Medison Pharma and Alpha Tau Medical Announce a Collaboration in the Oncology Field in Central and Eastern Europe

21/05/20

BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel

07/04/20

Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT

18/12/19

BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

21/01/19

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel